Rallybio Q4 net loss $11M, cash $65.5M; key trial data readouts in 2025

Rallybio Corp

Q4 2024 net loss $11.0M ($0.25/share) vs $20.2M ($0.50/share) in Q4 2023; full-year loss $57.8M.
Revenue $38k in Q4 2024 from J&J collaboration; zero revenue in year ago period.
Cash, equivalents, and marketable securities $65.5M as of Dec 31, 2024; runway into 2H 2026.
RLYB212 Phase 2 sentinel participant dosed; PK/safety data from 2nd trimester expected Q2 2025, at delivery Q3 2025.
RLYB116 confirmatory PK/PD study to start Q2 2025; Cohorts 1 and 2 data in Q3/Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.